Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02752074
Title A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

melanoma

Therapies

Epacadostat + Pembrolizumab

Pembrolizumab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.